10.08.2026 | Research | Virtual & Augmented Reality

ARTORG Start-Up PeriVision Demonstrates Clinical-Grade Performance

A new study conducted at University Hospital Bern (Inselspital) shows that VisionOne, PeriVision's VR-based eye-testing platform, delivers clinical performance comparable to the Octopus 900, a stationary perimeter considered the gold standard, across the full spectrum of glaucoma severity.

PeriVision is a spin-off coming out of ARTORG’s Artificial Intelligence in Medical Imaging (AIMI) research group that developed VisionOne, a platform that uses virtual reality glasses to measure the impact of glaucoma on visual fields – information that is crucial for the prevention and treatment of the disease.

The company shared on August 10, 2026, that a new prospective study at the Inselspital has confirmed that the VisionOne VR perimeter delivers clinical performance equivalent to the Octopus 900 – a stationary perimeter considered to be the gold standard. The study evaluated 73 patients (120 eyes) with mild, moderate and severe glaucoma, with each patient completing both examinations during the same visit.

This study, published in Ophthalmology Science, is a pivotal moment for VR perimetry, addressing the long-standing question regarding the accuracy of VR solutions in patients with advanced glaucoma.

“One of the main concerns surrounding virtual reality perimetry has been its limited ability to accurately assess patients with advanced glaucoma. We demonstrated that VisionOne maintains excellent agreement with the gold standard across the entire disease spectrum,” says Serife Kucur, CTO and co-founder of PeriVision.

Publication Details:

Colmenar Herrera, Marta; Hsin-Yang, Chen; Häner, Nathanael; Kucur Ergünay, Serife S.; Sznitman, Raphael; Zinkernagel, Martin S. (2026). “Evaluation of a Head-Mounted Virtual Reality Perimeter Compared with Stationary Perimeters across All Stages of Glaucoma,” Ophthalmology Science 6(9): 101314. Elsevier 10.1016/j.xops.2026.101314